Introduction to Targeted Therapies and Reconstruction

Advancements in targeted therapies have revolutionized treatment for triple-negative and hormone receptor-positive breast cancers. However, clinicians often worry about how these systemic treatments influence breast reconstruction surgical outcomes. A recent retrospective study investigated the complications associated with pembrolizumab and CDK4/6 inhibitors in patients undergoing immediate two-stage prepectoral reconstruction. While these drugs offer significant oncological benefits, their impact on wound healing and tissue integration requires careful evaluation by surgical teams.

Increased Risks with Pembrolizumab

The study found that patients receiving pembrolizumab faced a notably higher risk of postoperative issues. Specifically, the seroma rate during the expansion phase was 44.4% in the pembrolizumab group, compared to 27% in the control group. Furthermore, after the final implant exchange, major complications reached 26.3% for those on pembrolizumab. This led to a significantly higher reoperation rate of 19.1%. These findings suggest that immunotherapy may interfere with the early inflammatory environment necessary for stable reconstruction, leading to poorer breast reconstruction surgical outcomes.

CDK4/6 Inhibitors and Surgical Safety

In contrast, the use of CDK4/6 inhibitors appeared much safer regarding immediate reconstructive risks. Patients on these inhibitors did not experience an increased risk of infection following tissue expander placement. Interestingly, the observed rate of minor infections was lower in the CDK4/6 group at 0.0% versus 12.4% in others. Although these results are encouraging, surgeons should remain vigilant as long-term data on tissue quality and capsular contracture continue to emerge. Consequently, the safety profile of CDK4/6 inhibitors seems robust for patients seeking immediate prepectoral reconstruction.

Clinical Recommendations for Multidisciplinary Care

Effective management requires seamless communication between oncologists and plastic surgeons. Because pembrolizumab is associated with higher reoperation rates, surgeons might consider alternative timing or more intensive monitoring. Nevertheless, the study confirms that targeted therapies are not absolute contraindications to reconstruction. Tailoring the surgical plan to the specific drug regimen helps optimize patient recovery and aesthetic results. Future research should focus on the biological mechanisms behind immunotherapy-related seromas to improve overall breast reconstruction surgical outcomes.

Frequently Asked Questions

How does pembrolizumab affect the success of breast reconstruction?

Pembrolizumab significantly increases the risk of seroma formation and major complications requiring reoperation during two-stage prepectoral reconstruction. Patients should be closely monitored for fluid accumulation during the tissue expansion phase.

Are CDK4/6 inhibitors safe for patients undergoing immediate reconstruction?

Yes, current evidence suggests that CDK4/6 inhibitors do not increase the risk of infection or major surgical complications after tissue expander placement, making them relatively safe for use alongside reconstruction.

What are considered 'major complications' in these reconstruction studies?

Major complications are typically defined as adverse events that necessitate hospital readmission or a return to the operating room for surgical intervention, such as expander removal or debridement.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Ibrahim Y et al. Surgical Outcomes of Prepectoral Two-Stage Breast Reconstruction in Patients Treated with Pembrolizumab or CDK4/6 Inhibitors. Plast Reconstr PRS. 2026 Mar 13. doi: 10.1097/PRS.0000000000013032. PMID: 41825078.

2. Aldarayseh M et al. Unforeseen Complications of Pembrolizumab in Breast Reconstruction Post-Mastectomy. Eur J Case Rep Intern Med. 2024 Jul 1;11(7):004675.

3. Schmid P et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020;382:810-821.